NeuroOne Medical Technologies Corporation has elevated Emily Johns to the expanded role of Chief Administrative Officer and General Counsel, the company announced. Johns, who joined NeuroOne earlier this year as General Counsel, will continue leading legal strategy while assuming additional responsibilities for human resources, compliance, security and risk management across the organization. This executive promotion reflects NeuroOne's strategic focus on strengthening operational infrastructure as the company expands its portfolio of neurological treatments and maintains its Nasdaq listing under the symbol NMTC.
Dave Rosa, President and CEO of NeuroOne, emphasized Johns' immediate impact since joining the company. In the short time that Emily has been with NeuroOne she has made impactful contributions to the organization and the future growth of the business, Rosa stated. We look forward to her future contributions as we continue to scale our business. The promotion comes at a critical juncture as NeuroOne develops minimally invasive and high-definition solutions for EEG recording, stimulation and ablation for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other neurological disorders.
Johns brings extensive experience in public company law, having previously served as a partner at Honigman LLP where she represented numerous life sciences companies, including NeuroOne on transactional work since 2017. I am honored to step into this role and continue building on the strong foundation our exceptional team has created, Johns said. As we look ahead, I look forward to strengthening our operations and infrastructure to help bring our life-changing technologies to more people. The company's technologies aim to improve patient outcomes while reducing procedural costs, with additional information about the company's developments available at https://www.nmtc1.com.
This executive restructuring demonstrates NeuroOne's commitment to building robust operational frameworks necessary for scaling innovative medical technologies. By consolidating legal, human resources, compliance, security and risk management functions under Johns' leadership, the company positions itself for more efficient growth and enhanced corporate governance. The move signals confidence in Johns' ability to navigate the complex regulatory landscape of medical technology while supporting the company's expansion into new markets and treatment applications for neurological disorders.
